Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

remedyrepack inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 300 mg - reyataz ® (atazanavir) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: - reyataz is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus. - use of reyataz/ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology (12.4)] . reyataz is contraindicated:reyataz is contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (eg, stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of reyataz capsules or reyataz oral powder [see warnings and precautions (5.2)] . - when coadministered with drugs that are highly dependent on cyp3a or ugt1a1 for clearance, and for which elevated plasma concentrations of the interacting drugs are associated with serious and/or lif

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

remedyrepack inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 200 mg - reyataz ® (atazanavir) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: - reyataz is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus. - use of reyataz/ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology (12.4)] . reyataz is contraindicated:reyataz is contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (eg, stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of reyataz capsules or reyataz oral powder [see warnings and precautions (5.2)] . - when coadministered with drugs that are highly dependent on cyp3a or ugt1a1 for clearance, and for which elevated plasma concentrations of the interacting drugs are associated with serious and/or lif

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

physicians total care, inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 150 mg - reyataz® (atazanavir sulfate) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. this indication is based on analyses of plasma hiv-1 rna levels and cd4+ cell counts from controlled studies of 96 weeks duration in antiretroviral-naive and 48 weeks duration in antiretroviral-treatment-experienced adult and pediatric patients at least 6 years of age. the following points should be considered when initiating therapy with reyataz: - in study ai424-045, reyataz/ritonavir and lopinavir/ritonavir were similar for the primary efficacy outcome measure of time-averaged difference in change from baseline in hiv rna level. this study was not large enough to reach a definitive conclusion that reyataz/ritonavir and lopinavir/ritonavir are equivalent on the secondary efficacy outcome measure of proportions below the hiv rna lower limit of detection [see clinical studies (14.2) ]. - the number of baseline primary protease inhibitor mutations affects the virologic response to

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

avera mckennan hospital - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 150 mg - reyataz® (atazanavir) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: reyataz is contraindicated: table 6 displays drugs that are contraindicated with reyataz. drug class drugs within class that are contraindicated with reyataz clinical comment alpha 1-adrenoreceptor antagonist alfuzosin potential for increased alfuzosin concentrations, which can result in hypotension. antimycobacterials rifampin rifampin substantially decreases plasma concentrations of atazanavir, which may result in loss of therapeutic effect and development of resistance. antineoplastics irinotecan atazanavir inhibits ugt1a1 and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities. antipsychotics lurasidone potential for serious and/or life-threatening reactions if reyataz is coadministered with ritonavir. pimozide potential for serious and/or life-threatening reactions such

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

avera mckennan hospital - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 200 mg - reyataz® (atazanavir) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: reyataz is contraindicated: table 6 displays drugs that are contraindicated with reyataz. drug class drugs within class that are contraindicated with reyataz clinical comment alpha 1-adrenoreceptor antagonist alfuzosin potential for increased alfuzosin concentrations, which can result in hypotension. antimycobacterials rifampin rifampin substantially decreases plasma concentrations of atazanavir, which may result in loss of therapeutic effect and development of resistance. antineoplastics irinotecan atazanavir inhibits ugt1a1 and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities. antipsychotics lurasidone potential for serious and/or life-threatening reactions if reyataz is coadministered with ritonavir. pimozide potential for serious and/or life-threatening reactions such

Israel - Englisch - Ministry of Health

bristol - myers squibb, israel - atazanavir as sulfate - capsules - atazanavir as sulfate 200 mg - atazanavir - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - atazanavir sulfate, quantity: 341.69 mg (equivalent: atazanavir, qty 300 mg) - capsule, hard - excipient ingredients: crospovidone; magnesium stearate; lactose monohydrate; titanium dioxide; indigo carmine; iron oxide yellow; sorbitan monolaurate; iron oxide red; potable water; gelatin; iron oxide black; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; pharmaceutical glaze; dimeticone - reyataz is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see 5.1 pharmacodynamic properties: clinical trials).

Kanada - Englisch - Health Canada

mylan pharmaceuticals ulc - naproxen; esomeprazole (esomeprazole magnesium) - tablet (immediate and delayed-release) - 500mg; 20mg - naproxen 500mg; esomeprazole (esomeprazole magnesium) 20mg - other nonsteroidal antiimflammatory agents

Kanada - Englisch - Health Canada

mylan pharmaceuticals ulc - naproxen; esomeprazole (esomeprazole magnesium) - tablet (immediate and delayed-release) - 375mg; 20mg - naproxen 375mg; esomeprazole (esomeprazole magnesium) 20mg - other nonsteroidal antiimflammatory agents